Lifeloc Technologies, Inc. filings document a Colorado operating company that reports as an SEC registrant and trades common stock under LCTC. Its Form 8-K reports furnish operating results, Regulation FD releases, and material-event disclosures tied to the company’s breath alcohol and drug detection device business.
The filing record also covers material financing agreements, debt terms, security interests, capital-structure matters, and the use of proceeds for continued SpinDetect™ product development. Proxy materials describe annual shareholder voting matters, director elections, auditor ratification, governance procedures, and common-stock ownership information.
Lifeloc Technologies reported first-quarter 2026 revenue of $2,293,812, up about 1% year over year, driven by slightly higher product sales. Gross profit rose to $987,074, with product gross margin improving to 43% from 40% as cost of sales declined.
The company still posted a net loss of $152,713, but this was narrower than the $292,686 loss a year earlier, with lower research, development, and sales and marketing expenses helping offset higher interest costs. Cash and cash equivalents were $569,330 at March 31, 2026, versus current liabilities of $1,064,101, leaving a modest liquidity cushion.
Lifeloc continues to depend on its core breathalyzer business while investing heavily in its SpinDetect™ drug-detection platform, which it aims to launch commercially in 2026. After quarter-end it added a $500,000 secured loan from its CFO and Board Chairman at 10.5% interest to support development, increasing reliance on related-party financing and leverage.
Lifeloc Technologies, Inc. entered into a related-party loan transaction with its Chief Financial Officer and Chairman, Vern Kornelsen. The company issued a $500,000 Promissory Note dated May 1, 2026 to fund continued development of its SpinDetect™ product.
The Note carries an initial interest rate of 10.5% per annum, with interest-only payments through December 31, 2026. Starting January 31, 2027, it converts to sixty equal monthly payments of principal and interest, with final maturity on December 31, 2031, and an interest rate that may increase with changes in the prime rate.
The Note may be prepaid at any time without penalty and is secured by a Deed of Trust on Lifeloc’s principal office at 12441 West 49th Avenue, Wheat Ridge, Colorado, and by a security interest in substantially all company assets, both subordinated to existing senior indebtedness to Citywide Banks.
Lifeloc Technologies, Inc. is asking shareholders to approve several items at its June 3, 2026 annual meeting, including electing five directors, ratifying Assure CPA as auditor and holding an advisory “Say on Pay” vote on executive compensation.
A key proposal would adopt Amended and Restated Articles of Incorporation that both consolidate prior amendments and add a new foreign ownership provision. The board could redeem shares held by holders reasonably determined to be nationals or entities of U.S. Department of Energy “countries of risk,” at fair market value based on a 30‑day average closing bid price, after written notice and a 90‑day cure opportunity.
The proxy also details board and committee structure, director independence, modest director fees of $1,530 each for 2025, and 2025 executive pay, including total compensation of $302,518 for the CEO and $97,920 for the CFO, alongside a pay‑versus‑performance table showing recent net losses.
Lifeloc Technologies reported full-year 2025 revenue of $9.027 million, up 6% from $8.538 million in 2024, as demand for its breath alcohol testing products grew modestly while gross margin held essentially flat at 40.3%.
The company recorded a net loss of $2.470 million, or $(0.90) per diluted share, compared with a net loss of $1.053 million, or $(0.41), in 2024. Management explains the wider loss mainly reflects a non-cash increase in the deferred tax valuation allowance to $1.738 million, driven by recent loss history. Excluding this accounting change, loss before taxes improved slightly to $1.311 million from $1.405 million.
Cash and cash equivalents declined to $746,001 at December 31, 2025 from $1.244 million, with operating activities using $499,319 of cash and continued investment in property and R&D equipment. Total assets were $6.69 million and stockholders' equity was $4.10 million, down from $6.23 million a year earlier.
Lifeloc Technologies, Inc. reports its annual business update, highlighting steady breathalyzer operations and major investment in a new drug-testing platform. Product sales reached $8,958,672 in 2025, up 6% from 2024, with total revenues of $9,026,938. The company remains focused on fuel cell breathalyzers for law enforcement, workplace, corrections, OEM and international markets, now fully occupying its Wheat Ridge, Colorado headquarters after discontinuing a rental-property segment.
A key strategic initiative is SpinDetect™, a centrifugal microfluidic “lab-on-a-disk” system for rapid, quantitative drugs-of-abuse testing, including delta-9-THC. Lifeloc spent $2,152,843 on research and development and sustaining engineering in 2025 and added $354,381 of SpinDetect-related equipment, targeting an initial commercial launch in 2026. Management notes that continued progress will depend on access to capital, while also carrying subordinated debentures totaling $825,000 at 8.25% and a $1,350,000 mortgage maturing in 2031.
Lifeloc Technologies is registering 237,432 shares of common stock to issue as stock consideration in its proposed merger with Electronic Systems Technology (ELST). Each ELST share will be converted into the right to receive 0.048 Lifeloc shares, with cash paid instead of fractional shares. After closing, ELST will become a wholly owned subsidiary of Lifeloc and Lifeloc’s existing directors and officers will remain in place.
The merger requires approval by holders of at least 75% of ELST’s 4,946,502 outstanding shares as of December 11, 2025, at a special meeting on February 9, 2026. ELST’s board unanimously recommends voting for the deal, citing ELST’s limited growth prospects and lack of a trading market, while noting related-party ties, the absence of an independent fairness opinion, potential tax uncertainty over reorganization treatment, and available dissenters’ rights under Washington law.
Lifeloc Technologies is registering 237,432 shares of common stock to issue as stock consideration in its planned merger with Electronic Systems Technology (ELST). The Post‑Effective Amendment to the Form S‑4 updates the original registration with new merger disclosures, refreshed financial information, and conforming changes.
Under the Agreement and Plan of Merger, ELST will become a wholly owned subsidiary of Lifeloc, and each ELST share will convert into the right to receive 0.048 Lifeloc shares, with cash paid instead of fractional shares. ELST’s board unanimously approved the deal and recommends shareholders vote in favor, but approval requires at least 75% of ELST’s outstanding common stock. ELST holders have dissenters’ rights under Washington law to seek “fair value” instead of stock.
The filing highlights risks including integration challenges, related‑party conflicts due to overlapping directors and shareholders, the absence of an independent fairness opinion, uncertain U.S. federal tax treatment of the merger, and the lack of typical deal‑protection provisions, which could expose the transaction to delay or competing offers.
Lifeloc Technologies, Inc. (LCTC) furnished a press release announcing operating results for the period ended September 30, 2025. The company made the release available on its website on November 12, 2025 and attached it as Exhibit 99.1.
The information was furnished rather than filed, which means it is not subject to Section 18 liabilities and is not incorporated by reference into other filings unless expressly stated.
Lifeloc Technologies, Inc. reported Q3 2025 results. Total revenues were $2,257,448, with product sales of $2,241,331 (up 8% year over year). Gross profit was $906,693 (down 1%), reflecting higher costs. The quarter recorded a net loss of $263,439, or $0.10 per share.
For the nine months ended September 30, 2025, revenues were $6,753,858 and net loss was $949,764. Cash and cash equivalents were $685,097 as of September 30, 2025. Current liabilities were $907,861, and the company cited net liquid assets of $641,692. Outstanding debt was approximately $1.8M, including a term loan at 2.95% and subordinated debentures at 8.25%.
The company continues investing in SpinDetect™ development. Subsequent to quarter-end, it entered a merger agreement with Electronic Systems Technology, Inc.; an S‑4/A was filed on October 15, 2025, with closing subject to shareholder and regulatory approvals. Common shares outstanding were 2,752,616 as of November 10, 2025.
Lifeloc Technologies (LCTC) announced a merger agreement with Electronic Systems Technology (ELST). A newly formed Lifeloc subsidiary will merge into ELST, and ELST will continue as a wholly owned subsidiary of Lifeloc. ELST shareholders will receive Lifeloc common stock based on an agreed exchange ratio, with cash paid in lieu of fractional shares.
Closing is subject to customary conditions, including ELST shareholder approval, the effectiveness of a Form S-4 registration statement for the shares to be issued, and required regulatory approvals. The agreement includes customary representations, warranties, covenants, termination rights, and conditions.